---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-26-000010"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:21:42.912476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics reports 2025 net loss of $78.3M; Phase 2 HS topline data due Q2 2026

## Summary
- Net loss $78.3M ($5.84 per share) vs $35.1M in 2024; operating expenses rose to $73M.
- Cash, equivalents and short-term investments $98.3M as of Dec 31, 2025; expected runway into 2028.
- R&D expenses $50.1M, up $25.6M YoY driven by Phase 2 LOTUS trial costs for abdakibart (AVTX-009).
- Topline data from Phase 2 abdakibart trial for hidradenitis suppurativa expected in Q2 2026.
- G&A expenses $22.9M, up $5.7M primarily from stock-based compensation and headcount additions.

## SEC filing metadata
- accession: 0001534120-26-000010
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/0001534120-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/avtx-20260323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-26-000010
- JSON: https://secwatch.observer/filing/0001534120-26-000010.json
- Plain text: https://secwatch.observer/filing/0001534120-26-000010.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net loss was $78.3 million for the year ended December 31, 2025, EPS Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Net income: Net loss was $78.3 million for the year ended December 31, 2025
  - EPS: Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025
  - Result: reported results
  source text: On March 23, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/0001534120-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.